George Muschler, MD

Appointed
1988

Education & Fellowships

Fellowship - Memorial Sloan-Kettering Cancer Center
Musculoskeletal Oncology
New York, NY
1988

Fellowship - Weill Cornell Medical, Hospital for Special Surgery
Orthopaedic Surgery
New York, NY
1988

Residency - University of Texas Southwestern Medical Center
Orthopedic Surgery
Dallas, TX
1986

Internship - University of Texas Southwestern Medical Center
Surgical Internship
Dallas, TX
1982

Medical Education - Northwestern University Feinberg School of Medicine
Chicago, IL
1981

Undergraduate - University of Illinois Hospital at Urbana-Champaign
Chemistry
Urbana, IL
1977

Professional Highlights

• Director, Orthopaedic and Rheumatologic Research Center, 2005-Present
• Director, Clinical Tissue Engineering Center (CTEC), 2005-Present
• Vice Chairman, Department of Biomedical Engineering, 2004-Present
• Vice Chairman for Research, Cleveland Clinic Orthopaedic and Rheumatologic Institute, 2007-Present
• Co-Director, Armed Forces Institute for Regenerative Medicine (AFIRM), 2007-Present

Certifications

• Orthopaedic Surgery

Specialty Interests

Joint replacement surgery, treatment of fracture non-unions and avascular necrosis, research in regenerative tissue engineering, adult stem cell biology, health care quality assessment

Awards & Honors

• North American Traveling Fellowship, American Orthopaedic Association, 1989
• Career Development Award, Orthopaedic Research and Education Foundation, 1990-1992
• J.P Ranney Award for Innovation in Regenerative Medicine and Stem Cell Research, 2006
• Clevelands Best Doctors, Northern Ohio Live magazine, 2007

Innovations & Patents

• Innovator in both implant design for joint surgery and limb reconstruction, as well as in the application of biological principles to the regeneration of new tissues, particularly bone.  
• Responsible for over nine patents and recognized as inventor of the concept of selective retention as a means of rapidly concentrating and delivering a patient's own stem cells for use in tissue-healing applications. This is the basis for the Cellect TM Device, that has now been used in treatment of over 50,000 patients worldwide for bone repair following spine surgery or fractures.  

Memberships

• American Academy of Orthopaedic Surgeons
• Orthopaedic Research Society
• American Orthopaedic Association
• Association of Bone and Joint Surgeons
• International Society for Tissue Engineering
• International Society for Stem Cell Research
• American Society for Bone and Mineral Research

See publications for George Muschler, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/7/2024, Dr. Muschler has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Muschler receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Fortus Medical, Inc.

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Muschler may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

• Cell X Technologies, Inc.

Equity Dr. Muschler owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:

• Cell X Technologies, Inc.

Fiduciary Role. Dr. Muschler serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:

• Cell X Technologies, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.